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Background: No scoring system for assessing acute heart failure (AHF) has been reported.
Methods and results: Data for 824 AHF patients were analyzed. The subjects were divided into an alive
(n=750) and a dead group (n=74).We constructed a predictive scoring system based on eight signiﬁcant
APACHE II factors in the alive group [mean arterial pressure (MAP), pulse, sodium, potassium, hematocrit,
creatinine, age, and Glasgow Coma Scale (GCS); giving each one point], deﬁned as the APACHE-HF score.
The patients were assigned to ﬁve groups by the APACHE-HF score [Group 1: point 0 (n=70), Group 2:
points 1 and 2 (n=343), Group 3: points 3 and 4 (n=294), Group 4: points 5 and 6 (n=106), and Group
5: points 7 and 8 (n=11)]. A higher optimal balance was observed in the APACHE-HF between sensitivity
and speciﬁcity [87.8%, 63.9%; area under the curve (AUC) =0.779] at 2.5 points than in the APACHE II
(47.3%, 67.3%; AUC=0.558) at 17.5 points. The multivariate Cox regression model identiﬁed belonging
to Group 5 [hazard ratio (HR): 7.764, 95% conﬁdence interval (CI) 1.586–38.009], Group 4 (HR: 6.903,
95%CI 1.940–24.568) or Group 3 (HR: 5.335, 95%CI 1.582–17.994) to be an independent predictor of
3-year mortality. The Kaplan–Meier curves revealed a poorer prognosis, including all-cause death and
HF events (death, readmission-HF), in Group 5 and Group 4 than in the other groups, in Group 3 than in
Group 2 or Group 1, and in Group 2 than in Group 1.
Conclusions: The new scoring system including MAP, pulse, sodium, potassium, hematocrit, creatinine,
age, and GCS (APACHE-HF) can be used to predict adverse outcomes of AHF.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
The Acute Physiology and Chronic Health Evaluation (APACHE)
coring systemwas ﬁrst established in 1981 to predict the progno-
is in patients receiving intensive care (Fig. 1A) [1]. Subsequently,
he APACHE II, III, and IV systems were published over the past
0 years [2–4].
∗ Corresponding author at: Division of Intensive Care Unit, Chiba Hokusoh Hospi-
al, Nippon Medical School, 1715 Kamagari, Inzai, Chiba 270-1694, Japan.
el.: +81 476 99 1111; fax: +81 476 99 1911.
E-mail address: s6042@nms.ac.jp (A. Shirakabe).
ttp://dx.doi.org/10.1016/j.jjcc.2014.03.002
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reThe APACHE II system consists of three parts, including the
acute physiology score, chronic health points, and age points.
The total number of points for the three parts is calculated as the
APACHE II score. This score has been reported to be predictive
of adverse outcomes in patients requiring intensive care, such
as those with respiratory disease, severe pancreatitis, or severe
sepsis [5–9]. However, this scoring system involves many factors,
as described above; therefore, it cannot be applied easily, and
clinicians hesitate to use it in every patient.
In previous observational studies, various predictive factors for
detecting adverse outcomes in acute heart failure (AHF) patients
have been identiﬁed, including age [10], anemia [11], renal insuf-
ﬁciency [12,13], poor liver function [14], high uric acid [15], high
lactate [16], low cholesterol [12,16], elevated blood glucose [17],
served.
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Fig. 1. Deﬁnition of each scoring system. (A) The APACHE II scoring systemwas deﬁned in this study. (B) TheModiﬁed APACHE II scoring systemwas constructed based on the
signiﬁcant APACHE II factors in the alive group [mean blood pressure (BP), sodium, potassium, creatinine, age, and Glasgow Coma Scale (GCS)] and was given points based on
the APACHE II system. (C) The APACHE-HF scoring system was constructed based on the signiﬁcant APACHE II factors in the alive group (mean BP, pulse, sodium, potassium,
creatinine, hematocrit, age, and GCS) and was given one point for each cut-off value. The cut-off value for each factor was deﬁned by the receiver-operating characteristic
(ROC) curve as follows: mean BP [91.5mmHg, area under the ROC curve (AUC) =0.678, p<0.001), pulse (110.5 beats/min, AUC=0.594, p=0.008), sodium (137.5mmol/L,
AUC=0.613, p=0.001), potassium (4.85mmol/L, AUC=0.601, p=0.004), hematocrit (36.95mg/dL, AUC=0.617, p=0.001), creatinine (1.475mg/dL, AUC=0.676, p<0.001), age
(71.5 years, AUC=0.572, p=0.042) and GCS (13.5, AUC=0.567, p=0.058)].
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yperkalemia [12], hyponatremia [18], brain-type natriuretic pep-
ide (BNP), and left ventricular ejection fraction. With respect to
atients with AHF, no predictive scoring system has been estab-
ished, and evaluations of the APACHE II system have rarely been
eported. We therefore evaluated the efﬁcacy of the APACHE II and
ur newly established scoring system for AHF patients.
ethods
ubjects
Clinical data were collected from 824 patients with AHF who
ere admitted to the intensive care unit at ChibaHokusohHospital,
ippon Medical School between January 2000 and July 2012. AHF
as deﬁned as either new-onset HF or decompensation of chronic
F with symptoms sufﬁcient to warrant hospitalization [19]. HF
as diagnosed according to the Framingham criteria for a clinical
iagnosis of HF based on the satisfaction of two major criteria or
ne major and twominor criteria [20]. All patients had a New York
eart Association (NYHA) functional class of either Class III or IV.
HF patients with one of the following criteria were admitted to
he intensive care unit (ICU) by physician’s decision in the present
tudy: (1) patients who need high projectile oxygen inhalation
includingmechanical support) to treatorthopnea, (2)patientswho
eed intrope or mechanical support with low blood pressure, (3)
atients who need many types of diuretics to improve the general
r lung edema. Patients with HF caused by acute coronary syn-
romewere excluded from the study. All datawere retrospectively
etrieved from hospital medical records.
rocedure
AHF patients were divided into two groups according to in-
ospital mortality: the alive group (n=750) and the dead group
n=74).
We established two new scoring systems for AHF comparing
he two groups. First, we compared the APACHE II score between
he two groups using a univariate analysis. Factors associated with
igniﬁcantly more points in the alive group were selected to con-
truct the new scoring system. The total score of the signiﬁcant
actors in the alive group was deﬁned as the Modiﬁed APACHE II
core. Second,we compared the data for APACHE II factors between
he two groups using a univariate analysis. We then scored the
otal number of factors speciﬁc to survival discharge (giving one
oint for each factor), deﬁned as the APACHE-HF score. The cut-off
alue for each factor to give one point was deﬁned by the receiver-
perating characteristic (ROC) curves for the in-hospital mortality
f each factor.
We determined the scores (APACHE II, Modiﬁed APACHE II, and
PACHE-HF) in each patient based on data obtained at admission,
ccording to a previous report [2], and evaluated the sensitivity,
peciﬁcity, and positive and negative predictive value for differen-
iating the alive and dead groups. ROC curves were calculated to
redict the optimal cut-off values.
Furthermore, themid-term prognosis was evaluated in terms of
ll-cause death and HF events deﬁned as all-cause death or read-
ission due to HF. The patients were clinically followed up in a
outine outpatient clinic. For thepatients followedupat other insti-
utes, the ﬁnal prognosis was determined via telephone contact.
he patients were assigned to another two groups according to
he cut-off values of the ROC curves for the APACHE II, Modiﬁed
PACHE II, and APACHE-HF scores. The survival rates were then
nalyzed using Kaplan–Meier curves according to the APACHE II,
odiﬁedAPACHE II, andAPACHE-HFscores. Theprognosticvalueof
heAPACHE-HF score in these groups comparedwith that observediology 64 (2014) 441–449 443
in the group with lowest point as the referent was assessed using
a Cox regression hazard model.
Statistical analysis
All datawere statistically analyzedusing the SPSS20.0J software
program (SPSS Japan Institute, Tokyo, Japan). All numerical data
were expressed as themean± standard deviation ormedian (range
or 25–75% interquartile range) depending on normality. Unpaired
Student’s t-test or the Mann–Whitney U-test was used to compare
the twogroups. Normalitywas assessedusing the Shapiro–WilkW-
test. Comparisons of all proportions were made using a chi-square
analysis. A p-value of less than 0.05 was considered to be statisti-
cally signiﬁcant. ROC curves were calculated to predict the cut-off
values, and the sensitivity, speciﬁcity andarea, under theROCcurve
(AUC) were determined. The survival rates were analyzed between
the groups assigned based on the cut-off values of the ROC curves
for each scoring system using Kaplan–Meier curves, and signiﬁcant
differences were calculated using the log-rank test. A Cox regres-
sion analysis was performed to obtain the hazard ratios (HRs) for
90-daymortality and 90-day HF events. Subsequently, a multivari-
ate analysis was performed using the variables with a p-value of
<0.05 in the univariate analysis to examine their independent asso-
ciations with 90-day mortality and 90-day HF events. A p-value of
less than 0.05 was considered to be statistically signiﬁcant.
Ethical concerns
The institutional review board at Chiba Hokusoh Hospital, Nip-
pon Medical School approved the study protocol.
Results
Patient characteristics
The relationship between the treatment, including respiratory
support and medications prescribed during the ﬁrst 5 days, and
in-hospital mortality are shown in Table 1. The patient cohort
included 67.2% male subjects, with a median age of 74 years.
The systolic blood pressure (BP) values were signiﬁcantly lower,
the number of NYHA class IV patients was signiﬁcantly higher,
the serum hemoglobin levels were signiﬁcantly lower, the serum
urinary acid levels were signiﬁcantly higher, the serum BUN lev-
els were signiﬁcantly higher, the serum C-reactive protein (CRP)
levels were signiﬁcantly higher, and the serum BNP levels were
signiﬁcantly higher in the dead group than in the alive group.
Deﬁnition of the Modiﬁed APACHE II and APACHE-HF scoring
systems
Regarding the APACHE II score, the following six factors were
signiﬁcantly different between the alive group and the dead group:
mean BP, sodium, potassium, creatinine, age, and Glasgow Coma
Scale (GCS) (Table 2). We constructed a predictive scoring system
based on the signiﬁcant APACHE II factors in the alive group (mean
BP, sodium, potassium, creatinine, age, and GCS; giving points
based on the APACHE II system), deﬁned as the Modiﬁed APACHE
II score (Fig. 1B).
On the other hand, the following eight factors were sig-
niﬁcantly different between the alive group and dead group:
mean BP, pulse, sodium, potassium, hematocrit, creatinine, age,
and GCS (Table 3). We constructed a predictive scoring sys-
tem based on the signiﬁcant APACHE II factors in the alive
group (mean BP, pulse, sodium, potassium, creatinine, hemat-
ocrit, age, and GCS; giving one point based on each cut-off value),
deﬁned as the APACHE-HF score (Fig. 1C). The cut-off values for
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Table 1
Relationships between the patient characteristics and in-hospital survival.
Characteristic Total (n=824) Dead group (n=74) Alive group (n=750) p-Value
Age (years) 74 (65–80) 74 (64–80) 76 (70–81) 0.041
Gender (male, %) 554 (67.2%) 44 (59.5%) 510 (68.0%) 0.153
Type (new onset, %) 544 (66.0%) 43 (58.1%) 501 (66.8%) 0.157
Etiology
Ischemic heart disease (yes, %) 554 (67.2%) 44 (59.5%) 510 (68.0%) 1.000
Cardiomyopathy (yes, %) 141 (17.1%) 14 (18.9%) 127 (16.9%) 0.630
Hypertensive heart disease (yes, %) 143 (17.4%) 7 (9.5%) 136 (18.1%) 0.076
Valvular (yes, %) 117 (21.5%) 20 (27.0%) 157 (20.9%) 0.236
Others (yes, %) 22 (2.7%) 2 (2.7%) 20 (2.7%) 1.000
Past medical history
Hypertension (yes, %) 612 (74.3%) 47 (63.5%) 565 (75.3%) 0.036
Diabetes mellitus (yes, %) 341 (41.4%) 32 (43.2%) 309 (41.2%) 0.805
Dyslipidemia (yes, %) 374 (45.4%) 25 (33.8%) 349 (46.5%) 0.038
Vital signs and status
SBP (mmHg) 160 (132–186) 131 (107–168) 162 (138–188) <0.001
SBP>140mmHg (yes, %) 559 (67.8%) 31 (41.9%) 528 (70.4%) <0.001
SBP 100–140mmHg (yes, %) 232 (28.2%) 29 (39.2%) 203 (27.1%) 0.031
SBP<100mmHg (yes, %) 66 (8.0%) 13 (17.6%) 53 (7.1%) 0.005
Diastolic blood pressure (mmHg) 90 (70–100) 80 (62–90) 90 (72–100) <0.001
LVEF (%) 35.0 (25–46) 32 (22–45) 35 (24–46) 0.150
LVEF>40% (%) 295 (36.0%) 23 (31.9%) 272 (36.4%) <0.001
NYHA (IV, %) 667 (80.9%) 66 (89.2%) 601 (80.1%) 0.003
Laboratory data
Total bilirubin (mg/dL) 0.6 (0.4–0.8) 0.7 (0.4–1.0) 0.6 (0.4–0.8) 0.166
Urinary acid (mg/dL) 6.8 (5.5–8.1) 7.7 (5.9–9.6) 6.7 (5.3–8.0) 0.001
BUN (mg/dL) 23.2 (17.9–33.1) 36.4 (21.5–48.7) 22.7 (17.5–31.8) <0.001
Hemoglobin (g/dL) 12.5 (10.7–14.5) 11.3 (10.3–14.2) 12.5 (10.8–14.5) 0.001
CRP (mg/dL) 0.56 (0.19–1.78) 1.44 (0.56–4.58) 0.52 (0.17–1.63) <0.001
BNP (pg/mL) 805 (415–1403) 1363 (927–1787) 753 (399–1312) <0.001
Respiratory support
Endotracheal intubation (yes, %) 209 (25.4%) 36 (48.6%) 173 (23.1%) <0.001
NPPV (yes, %) 310 (37.6%) 24 (32.4%) 286 (38.1%) 0.380
Medication (cases) during the ﬁrst 5 days
Furosemide (yes, %) 781 (94.8%) 66 (89.2%) 715 (95.3%) 0.047
Nitroglycerin (yes, %) 594 (69.1%) 37 (50.0%) 557 (74.3%) <0.001
Nicorandil (yes, %) 95 (11.5%) 11 (14.9%) 84 (11.2%) 0.341
Carperitide (yes, %) 449 (54.5%) 45 (60.8%) 404 (53.9%) 0.272
Dopamine (yes, %) 238 (28.9.0%) 41 (55.4%) 197 (26.3%) <0.001
Dobutamine (yes, %) 117 (21.5%) 36 (48.6%) 141 (18.8%) <0.001
ACE-I/ARB (yes, %) 333 (40.4%) 17 (22.9%) 316 (42.1%) 0.001
-Blocker (yes, %) 196 (23.8%) 16 (21.6%) 180 (24.0%) 0.775
Spironolactone (yes, %) 296 (35.9%) 18 (24.3%) 278 (37.1%) 0.031
Outcome
ICU hospitalization (days) 5 (3–7) 7 (4–17) 5 (3–7) <0.001
Total hospitalization (days) 29 (18–49) 30 (13–82) 29 (18–47) 0.489
SBP, systolic blood pressure; LVEF, left ventricular ejection fraction measured on echocardiography; NYHA, New York Heart Association; BUN, blood urea nitrogen; CRP,
C-reactive protein; BNP, brain natriuretic peptide; NPPV, non-invasive positive pressure ventilation; ACE-I, angiotensin-converting enzyme inhibitor ARB, angiotensin II
receptor blocker; ICU, intensive care unit.
p-Value between the alive group and dead group determined according to unpaired Student’s t-test and Mann–Whitney U-test.
Table 2
Relationships between the APACHE II score and in-hospital mortality.
All (n=825) Alive group (n=750) Dead group (n=75) p-Value
Total APS
Body temperature (◦C) 0.39 ± 0.57 0.38 ± 0.55 0.51 ± 0.67 0.162
Mean blood pressure (mmHg) 1.51 ± 1.36 1.54 ± 1.36 1.22 ± 1.33 0.036
Pulse (beats/min) 1.53 ± 1.23 1.54 ± 1.22 1.39 ± 1.24 0.227
Respiratory rate (per min) 1.36 ± 1.20 1.36 ± 1.19 1.38 ± 1.27 0.920
A-aDO2 (FiO2 >0.5) or PaO2 (FiO2 <0.5) 0.91 ± 1.46 0.90 ± 1.45 1.00 ± 1.52 0.778
pH 1.59 ± 1.60 1.59 ± 1.60 1.58 ± 1.51 0.985
Sodium (mmol/L) 0.05 ± 0.35 0.04 ± 0.31 0.18 ± 0.60 0.001
Potassium (mmol/L) 0.22 ± 0.66 0.19 ± 0.61 0.46 ± 0.91 0.021
Hematocrit (%) 0.55 ± 0.90 0.54 ± 0.90 0.61 ± 0.88 0.511
Creatinine (mg/dL) 0.96 ± 1.35 0.90 ± 1.32 1.61 ± 1.51 <0.001
White blood cell (/m3) 0.16 ± 0.44 0.16 ± 0.44 0.14 ± 0.40 0.873
Age points 5.05 ± 1.26 5.01 ± 1.29 5.39 ± 0.90 0.027
Chronic health points 0.53 ± 1.54 0.51 ± 1.52 0.68 ± 1.63 0.386
Glasgow Coma Scale 0.94 ± 2.49 0.88 ± 2.40 1.59 ± 2.90 0.006
APS, acute physiology score.
p-Value between the alive group and dead group determined according to Mann–Whitney U-test.
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Table 3
Relationships between the APACHE II data and in-hospital mortality.
All (n=824) Alive group (n=750) Dead group (n=74) p-Value
Total APS
Body temperature (◦C) 36.3 (35.7–36.8) 36.2 (35.7–36.8) 36.4 (35.2–36.9) 0.750
Mean blood pressure (mmHg) 112.0 (94–130) 113 (95–131) 97 (77–114) <0.001
Pulse (beats/min) 114 (95–132) 116 (96–132) 105 (82–125) 0.008
Respiratory rate (per min) 30 (23–35) 30 (24–35) 30 (23–35) 0.411
PaO2 (mmHg) 86.7 (65.5–128.7) 85.8 (65.5–123.8) 96.1 (67.2–147.5) 0.136
pH 7.32 (7.20–7.42) 7.32 (7.19–7.42) 7.21 (7.19–7.40) 0.873
Sodium (mmol/L) 140 (137–142) 140 (138–142) 137 (135–141) 0.001
Potassium (mmol/L) 4.3 (3.9–4.7) 4.2 (3.9–4.7) 4.4 (3.9–5.2) 0.004
Hematocrit (%) 38.0 (33.2–43.7) 38.5 (33.7–44.0) 34.7 (30.7–39.7) 0.001
Creatinine (mg/dL) 1.16 (0.91–1.73) 1.13 (0.89–1.67) 1.63 (1.15–2.55) <0.001
White blood cell (/m3) 9775 (7600–12,653) 9795 (7645–12,668) 9625 (6890–12,353) 0.300
Age (years) 74 (65–80) 74 (64–80) 76 (70–81) 0.041
Chronic health points 0 (0–0) 0 (0–0) 0 (0–0) 0.386
Glasgow Coma Scale 15 (15–15) 15 (15–15) 15 (13–15) 0.006
APS, acute physiology score.
p-Value between the alive group and dead group determined according to Mann–Whitne
Fig. 2. ROC curves for each scoring system. The APACHE II system demonstrated an
optimal balance between sensitivity and speciﬁcity (47.3% and 67.3%; AUC=0.588,
p=0.012) at 17.5 points (black line), while the Modiﬁed APACHE II system demon-
strated anoptimal balance between sensitivity and speciﬁcity (51.4% and69.4%, AUC
0.590, p=0.001) at 9.5 points (blue line) and the APACHE-HF system demonstrated
an optimal balance between sensitivity and speciﬁcity (87.8% and 63.9%, AUC 0.779,
p<0.001) at 2.5 points (red line). ROC, receiver-operating characteristic; AUC, area
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ach factor were deﬁned by ROC curves as follows: mean BP
91.5mmHg, AUC=0.678), pulse (110.5 beats/min, AUC=0.594),
odium (137.5mmol/L, AUC=0.613), potassium (4.85mmol/L,
UC=0.601), hematocrit (36.95mg/dL, AUC=0.617), creatinine
1.475mg/dL, AUC=0.676), age (71.5 years, AUC=0.572), and GCS
13.5, AUC=0.567).
redictive value of the Modiﬁed APACHE II and APACHE-HF
coring systems
TheAPACHE II demonstrated an optimal balance between sensi-
ivity and speciﬁcity (47.3% and 67.3%; AUC=0.588) at 17.5 points,
electing 9.5 points for the Modiﬁed APACHE II score as a cut-off
alue (sensitivity 51.4%, speciﬁcity 69.4%, AUC 0.590). Meanwhile,
cut-off value of 2.5 points for the APACHE-HF score produced
n optimal balance (sensitivity 87.8%, speciﬁcity 63.9%, AUC 0.779)
Fig. 2). A higher optimal balance was observed in the APACHE-HF
core than in the APACHE II or Modiﬁed APACHE II scores.y U-test.
Based on these cut-off values, the patientswere divided into low
or high groups for each scoring system. The Kaplan–Meier survival
curves showed that the prognosis, including all-cause death, did
not differ between the patients with an APACHE II score of ≤17 and
those with an APACHE II score of ≥18. Meanwhile, the prognosis
was signiﬁcantly poorer in the patients with a Modiﬁed APACHE II
scoreof≥10 than in thosewithaModiﬁedAPACHE II scoreof≤9and
in the patients with an APACHE-HF score of ≥3 than in those with
an APACHE II-HF score of ≤2 (Fig. 3A, C, and E). The Kaplan–Meier
survival curves showed that theprognosis, includingHFevents,was
signiﬁcantly poorer in the patients with an APACHE II score of ≥18,
a Modiﬁed APACHE II score of ≥10, and an APACHE-HF score of ≥3
than in thosewith an APACHE II score of ≤17, aModiﬁed APACHE II
of ≤9, and an APACHE-HF score of ≤2, respectively (Fig. 3B, D, and
F).
The patientswere assigned to ﬁve groups based on the APACHE-
HF score [Group1: point 0 (n=70), Group2: points 1 and2 (n=343),
Group 3: points 3 and 4 (n=294), Group 4: points 5 and 6 (n=106)
and Group 5: points 7 and 8 (n=11)].
The multivariate Cox regression model identiﬁed belong-
ing to Group 3 (HR: 7.700, 95%CI 0.935–63.421), Group 4
(HR: 12.357, 95%CI 1.388–110.010), or Group 5 (HR: 18.361, 95%CI
1.478–228.145) as independent predictors of 90-day mortality
(Table4). Furthermore, themultivariateCox regressionmodel iden-
tiﬁed belonging to Group 2 (HR: 3.253, 95%CI 1.173–9.019), Group
3 (HR: 5.298, 95%CI 1.842–15.238), Group 4 (HR: 6.201, 95%CI
2.040–18.846), orGroup5 (HR: 9.413, 95%CI 2.432–36.436) as inde-
pendentpredictorsofHFeventsduring the90-day follow-upperiod
(Table 4). The Kaplan–Meier curves revealed a poorer prognosis,
including all-cause death and HF events, in Group 5 and Group 4
than in the other groups, in Group 3 than in Group 2 or Group 1,
and in Group 2 than in Group 1 (Fig. 4).
Discussion
In the present study, the APACHE II scoring system did not
exhibit an adequate AUC. Furthermore, the Modiﬁed APACHE II
scoring system was inadequate to predict the mid-term mortality.
The new scoring system named APACHE-HF, which comprised
a combination of parameters, including mean BP, pulse, sodium,cantly higher sensitivity and speciﬁcity with an adequate AUC and
could be used to predict adverse mid-term outcomes in patients
with AHF.
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Fig. 3. Kaplan–Meier curves for each scoring system. (A) The prognosis, including all-cause death, did not differ between the patients with an APACHE II score of ≤17 and
those with an APACHE II score of ≥18. (B) The prognosis, including HF events, was signiﬁcantly poorer in the patients with an APACHE II score of ≥18 than in those with an
APACHE II score of ≤17. (C) The prognosis, including all-cause death, was signiﬁcantly poorer in the patients with a Modiﬁed APACHE II score of ≥10 than in those with a
Modiﬁed APACHE II score of ≤9. (D) The prognosis, including HF events, was signiﬁcantly poorer in the patients with a Modiﬁed APACHE II score of ≥10 than in those with
a Modiﬁed APACHE II score of ≤9. (E) The prognosis, including all-cause death, was signiﬁcantly poorer in the patients with an APACHE-HF score of ≥3 than in those with
an APACHE II-HF score of ≤2. (F) The prognosis, including HF events, was signiﬁcantly poorer in the patients with an APACHE-HF score of ≥3 than in those with an APACHE
II-HF score of ≤2. HF, heart failure.
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Table 4
Cox regression analysis of the associations between 90-days cumulative mortality and events, and the clinical ﬁndings.
Univariate analysis Multivariate analysis
HR 95%CI p-Value HR 95%CI p-Value
90-days mortality
Points of APACHE-HF score
Group 1 (point 0) 1.000 1.000
Group 2 (point 1, point 2) 1.221 0.147–10.139 0.854 1.110 0.127–9.694 0.925
Group 3 (point 3, point 4) 7.603 1.038–55.694 0.046 7.700 0.935–63.421 0.058
Group 4 (point 5, point 6) 17.522 2.366–129.756 0.005 12.357 1.388–110.010 0.024
Group 5 (point 7, point 8) 20.637 2.147–198.405 0.009 18.361 1.478–228.145 0.024
Adjusting factors
APACHE II (per 1 point increase) 1.054 1.013–1.097 0.009 1.011 0.936–1.092 0.780
Modiﬁed APACHE II (per 1 point increase) 1.120 1.061–1.183 <0.001 0.992 0.879–1.120 0.900
LVEF (per 1% increase) 0.987 0.970–1.003 0.987
NYHA (class IV) 2.352 1.015–5.451 0.046 2.486 0.918–6.729 0.073
Total bilirubin (per 0.1mg/dL increase) 1.011 0.997–1.026 0.120
BUN (per 1.0mg/dL increase) 1.026 1.017–1.036 <0.001 1.015 1.002–1.029 0.024
Hemoglobin (per 1.0 g/dL increase) 0.861 0.786–0.945 0.002 1.107 0.974–1.258 0.118
BNP (per 10pg/mL increase) 1.002 1.001–1.003 0.007 1.001 0.999–1.003 0.269
90-days HF Events
Points of APACHE-HF score
Group 1 (point 0) 1.000 1.000
Group 2 (point 1, point 2) 4.315 1.582–11.769 0.004 3.253 1.173–9.019 0.023
Group 3 (point 3, point 4) 7.047 2.597–19.125 <0.001 5.298 1.842–15.238 0.002
Group 4 (point 5, point 6) 10.723 3.870–29.717 <0.001 6.201 2.040–18.846 0.001
Group 5 (point 7, point 8) 14.126 4.135–48.261 <0.001 9.413 2.432–36.436 0.001
Adjusting factors
APACHE-II (per 1 point increase) 1.032 1.011–1.053 0.002 0.983 0.946–1.021 0.371
Modiﬁed APACHE II (per 1 point increase) 1.082 1.050–1.115 <0.001 1.039 0.978–1.103 0.220
LVEF (per 1% increase) 0.991 0.983–0.999 0.033 0.989 0.980–0.998 0.023
NYHA (class IV) 1.723 1.189–2.497 0.004 1.778 1.165–2.715 0.008
Total bilirubin (per 0.1mg/dL increase) 1.086 0.996–1.184 0.061
BUN (per 1.0mg/dL increase) 1.019 1.013–1.025 <0.001 1.013 1.005–1.020 0.001
Hemoglobin (per 1.0 g/dL increase) 0.925 0.883–0.968 0.001 1.021 0.954–1.092 0.553
BNP (per 10pg/mL increase) 1.001 1.001–1.002 0.001 1.000 0.999–1.001 0.461
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lood urea nitrogen; CRP, C-reactive protein; BNP, brain natriuretic peptide.
PACHE II scoring system and AHF
The APACHE II scoring systemwas ﬁrst published in 1985, and it
asbeendemonstrated that an increasedAPACHE II scoreonadmis-
ion can be used to predict a worse in-hospital mortality and poor
ong-term prognosis in intensive care patients [2]. The availability
f this scoring system has also been reported in the setting of both
ndogenous and various surgical diseases requiring intensive care,
uch as respiratory disease, abdominal sepsis, including acute pan-
reatitis, trauma, and postoperative diseases [6–9]. However, this
coring system has not been evaluated in AHF patients. Moreover,
he APACHE II scoring system involves many factors and is cum-
ersome to apply; therefore, clinicians tend to hesitate to calculate
he score in all patients. It is necessary to develop a scoring system
hat can be more easily and immediately applied in the emergency
epartment.
In the present study, the APACHE II scoring system was found
o have an inadequate AUC, while the Modiﬁed APACHE II sco-
ing system could not be used to predict the mid-term mortality.
his might be due to inadequacies in the APACHE II point system.
he APACHE II scoring scale was originally developed for patients
ith various diseases requiring care in the intensive care unit. In
act, the majority of patients evaluated in the original study of
he APACHE II scoring system had non-cardiac diseases. Cardiac
atients comprisedonly14.7%of cases,withHFpatients accounting
or less than 1.5%. We therefore created a new scoring system suit-
ble for HF patients based on a simple point method. This system
s deﬁned as the APACHE-HF system, which exhibits signiﬁcantly
igher sensitivity and speciﬁcity with an adequate AUC compared
o the APACHE II and Modiﬁed APACHE II systems. Based on the
esults of the present study, a combination of parameters, includingraction measured on echocardiography; NYHA, New York Heart Association; BUN,
meanBP, pulse, sodium,potassium, creatinine, hematocrit, age, and
GCS, may be used to predict adverse outcomes of AHF.
Predictive factors for AHF
In previous observational studies, various predictive factors for
detecting adverse outcomes in AHF patients have been identiﬁed.
Among these factors,weshowedthemeanBP,pulse, sodium,potas-
sium, creatinine, hematocrit, age, and GCS at the time of admission
to be predictive factors in AHF patients.
An age over 70 or 75 years has been reported to be associated
with a poor prognosis [12,14]. In addition, hypotension is one of the
most important determinants of the prognosis. Gheorghiade et al.
reported that a systolic pressure under 120mmHg at the time of
admission was associated with a poor prognosis compared with a
systolic pressure over 120mmHg [10,21]. It has also been reported
that a diastolic pressure under 100mmHg or 90mmHg on admis-
sion is associated with poor mortality [14,22]. According to a study
of mean arterial BP, a diastolic pressure under 90mmHg is a strong
predictor of AHF [23]. We used the pulse rate as a substitute for
heart rate, which is a strong predictor of cardiovascular mortal-
ity and morbidity in the general population [24]. With respect to
AHF, Aaronson et al. found, in a study of 268 ambulatory patients
with advanced HF, that the resting heart rate was the best pre-
dictor of an adverse outcome [25,26]. In another example, Ishii
et al. showed that a heart rate over 113beats/min on admission
is associated with a better cardiac event-free survival rate than a
heart rate under 112beats/min [27]; these ﬁndings support our
results. Hyponatremia is themost commonelectrolyte abnormality
in patients with AHF. In several large clinical trials, hyponatremia
was demonstrated to predict a poor prognosis [14,20,28]. The
448 H. Okazaki et al. / Journal of Card
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Fig. 4. Kaplan–Meier curves for the APACHE-HF scoring system. (A) The
Kaplan–Meier curves revealed a poorer prognosis, including all-cause death, in
Group 5 and Group 4 than in the other groups, in Group 3 than in Group 2 or Group
1, and in Group 2 than in Group 1. (B) The Kaplan–Meier curves revealed a poorer
p
i
f
p
t
s
t
r
t
u
i
v
t
t
krognosis, including HF events, in Group 5 and Group 4 than in the other groups,
n Group 3 than in Group 2 or Group 1, and in Group 2 than in Group 1. HF, heart
ailure.
resent study also demonstrated a correlation between hypona-
remia andhighmortality orHF events, and the cut-off value for the
erum sodium level (Na 137mmol/L.) was similar to the conven-
ional deﬁnition of hyponatremia (Na<135mmol/L). Although the
elationship between hematocrit and the prognosis of HF remains
o be elucidated, anemia is a famous comorbidity of heart fail-
re and has been reported to be a predictor of poor outcomes
n patients with chronic and acute HF [29]. Although most pre-
ious studies used the hemoglobin level as a marker of anemia,
he present study employed hematocrit because it is a constitu-
ive factor of the APACHE II score. Renal dysfunction is also well
nown to be a strong predictor of AHF, and the prognosis of AHFiology 64 (2014) 441–449
depends on the degree of renal dysfunction [30,31]. For example, in
the data from the AHEAD registry, patients with a creatinine level
of >120mmol/L on admission had a poor prognosis [15]. In another
report, a serum creatinine level over 1.5mg/dL or 2.0mg/dL on
admissionwas found to be a predictor ofmortality [22,23]. Because
patients with AHF and anemia present more frequently with sig-
niﬁcant renal dysfunction, renal dysfunction as a predictor of AHF
may have relevance to anemia. No relationship between the serum
potassium level on admission and the prognosis of AHF has been
reported to date; however, this phenomenon may be explained by
an association with renal dysfunction. The relationship between
consciousness disturbance on admission andAHFhasnot been ade-
quately reported. Sicker AHF patients with shock and acidosis tend
to exhibit consciousness disturbance on admission. The level of
consciousness on admission is therefore a possible factor indicating
the general condition of AHF patients.
NoAHF scoring systems including these key factors forAHFhave
been previously reported; however, the development of a scoring
system that can be applied more easily and immediately in the
emergency department would be useful in the clinical setting for
treating AHF patients.
Study limitations
There are several limitations associated with the present study
that should be considered when interpreting the results. First, the
original APACHE II scoring systemwas based on themost deranged
(worst) physiologic value observed during the initial 24-h time
period assuming that all pertinent physiologic values were avail-
able. In the present study, we used vital signs and laboratory data
obtained on admission because AHF patients are in the most criti-
cal condition on admission. Therefore, this system may not reﬂect
the worst condition of AHF patients. Second, the population evalu-
ated in our study was limited to only patients admitted to the ICU,
and AHF patients admitted to general wards were excluded from
this study. However, the patients were seen by the “closed ICU” in
our institute, and all physicians in “closed ICU” are cardiologists.
Therefore, the majority of AHF patients were admitted to the ICU.
For example, the rate of CS1, CS2, and CS 3 (67.8%, 28.1%, and 8%)
patients were not different to the previous ATTEND registry with
hospitalizedHF (49.5%, 42.4%, and7.9%) [32]. Thepatients’ selection
biasmightbeminimal in thepresent study. Third,wepersistedwith
the evaluation of original APACHE II, therefore, the scoring system
did not include the widely accepted factors such as left ventricular
ejection fraction, NYHAclass, bloodurea nitrogen, hemoglobin, and
BNP. Further study will be needed to evaluate these factors for the
next new scoring system.
Conclusion
TheAPACHE II scoring system cannot be used to adequately pre-
dict the prognosis of patients with AHF. Our new scoring system
including mean BP, pulse, sodium, potassium, hematocrit, creati-
nine, age, and GCS was found to be effective in predicting adverse
outcomes in AHF patients.
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